Does the media refer more to TCMD or INGN?

In the previous week, Tactile Systems Technology had 2 more articles in the media than Inogen. MarketBeat recorded 5 mentions for Tactile Systems Technology and 3 mentions for Inogen. Tactile Systems Technology's average media sentiment score of 0.42 beat Inogen's score of 0.20 indicating that Tactile Systems Technology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tactile Systems Technology 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Inogen 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer SGP or INGN?

Spyglass Pharma presently has a consensus target price of $45.00, suggesting a potential upside of 122.00%. Given Spyglass Pharma's stronger consensus rating and higher probable upside, equities research analysts plainly believe Spyglass Pharma is more favorable than Inogen. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spyglass Pharma 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 Inogen 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Does the media prefer SGP or INGN?

In the previous week, Spyglass Pharma had 2 more articles in the media than Inogen. MarketBeat recorded 5 mentions for Spyglass Pharma and 3 mentions for Inogen. Inogen's average media sentiment score of 0.20 beat Spyglass Pharma's score of -0.12 indicating that Inogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyglass Pharma 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Inogen 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate MDXG or INGN?

MiMedx Group presently has a consensus price target of $8.50, suggesting a potential upside of 96.76%. Given MiMedx Group's stronger consensus rating and higher possible upside, research analysts plainly believe MiMedx Group is more favorable than Inogen. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MiMedx Group 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71 Inogen 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has better earnings & valuation, MDXG or INGN?

MiMedx Group has higher revenue and earnings than Inogen. Inogen is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MiMedx Group $418.63M 1.54 $48.58M $0.20 21.60 Inogen $348.67M 0.50 -$22.75M -$0.91 N/A

Is MDXG or INGN more profitable?

MiMedx Group has a net margin of 7.88% compared to Inogen's net margin of -7.08%. MiMedx Group's return on equity of 21.03% beat Inogen's return on equity. Company Net Margins Return on Equity Return on Assets MiMedx Group 7.88% 21.03% 15.92% Inogen -7.08% -12.90% -8.27%

Does the media refer more to MDXG or INGN?

In the previous week, Inogen had 1 more articles in the media than MiMedx Group. MarketBeat recorded 3 mentions for Inogen and 2 mentions for MiMedx Group. MiMedx Group's average media sentiment score of 0.34 beat Inogen's score of 0.20 indicating that MiMedx Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiMedx Group 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Inogen 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend INGN or BWAY?

Brainsway has a consensus target price of $15.67, suggesting a potential downside of 2.99%. Given Brainsway's stronger consensus rating and higher possible upside, analysts clearly believe Brainsway is more favorable than Inogen. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inogen 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Brainsway 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20

Which has preferable earnings and valuation, INGN or BWAY?

Brainsway has lower revenue, but higher earnings than Inogen. Inogen is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inogen $348.67M 0.50 -$22.75M -$0.91 N/A Brainsway $56.22M 11.53 $7.57M $0.35 46.14

Is INGN or BWAY more profitable?

Brainsway has a net margin of 15.68% compared to Inogen's net margin of -7.08%. Brainsway's return on equity of 12.28% beat Inogen's return on equity. Company Net Margins Return on Equity Return on Assets Inogen -7.08% -12.90% -8.27% Brainsway 15.68% 12.28% 7.75%

Does the media prefer INGN or BWAY?

In the previous week, Brainsway had 7 more articles in the media than Inogen. MarketBeat recorded 10 mentions for Brainsway and 3 mentions for Inogen. Brainsway's average media sentiment score of 0.75 beat Inogen's score of 0.20 indicating that Brainsway is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inogen 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Brainsway 2 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer INGN or NPCE?

NeuroPace has a consensus price target of $18.83, indicating a potential upside of 21.82%. Given NeuroPace's stronger consensus rating and higher probable upside, analysts plainly believe NeuroPace is more favorable than Inogen. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inogen 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 NeuroPace 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 2.88

Which has higher valuation and earnings, INGN or NPCE?

NeuroPace has lower revenue, but higher earnings than Inogen. NeuroPace is trading at a lower price-to-earnings ratio than Inogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inogen $348.67M 0.50 -$22.75M -$0.91 N/A NeuroPace $99.99M 5.27 -$21.47M -$0.65 N/A

Is INGN or NPCE more profitable?

Inogen has a net margin of -7.08% compared to NeuroPace's net margin of -21.67%. Inogen's return on equity of -12.90% beat NeuroPace's return on equity. Company Net Margins Return on Equity Return on Assets Inogen -7.08% -12.90% -8.27% NeuroPace -21.67% -108.20% -18.50%

Inogen (INGN) Competitors

$6.43 +0.03 (+0.47%)

Closing price 07/21/2026 04:00 PM Eastern

Extended Trading

$6.50 +0.07 (+1.01%)

As of 07/21/2026 07:34 PM Eastern

Compare

INGN vs. TCMD, SGP, MDXG, BWAY, and NPCE

Should you buy Inogen stock or one of its competitors? MarketBeat compares Inogen with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Inogen include Tactile Systems Technology (TCMD), Spyglass Pharma (SGP), MiMedx Group (MDXG), Brainsway (BWAY), and NeuroPace (NPCE). These companies are all part of the "medical equipment" industry.

How does Inogen compare to Tactile Systems Technology?

Tactile Systems Technology (NASDAQ:TCMD) and Inogen (NASDAQ:INGN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk, profitability and media sentiment.

Tactile Systems Technology has a net margin of 5.91% compared to Inogen's net margin of -7.08%. Tactile Systems Technology's return on equity of 9.70% beat Inogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tactile Systems Technology	5.91%	9.70%	7.53%
Inogen	-7.08%	-12.90%	-8.27%

83.4% of Tactile Systems Technology shares are owned by institutional investors. Comparatively, 89.9% of Inogen shares are owned by institutional investors. 2.1% of Tactile Systems Technology shares are owned by company insiders. Comparatively, 2.5% of Inogen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Tactile Systems Technology had 2 more articles in the media than Inogen. MarketBeat recorded 5 mentions for Tactile Systems Technology and 3 mentions for Inogen. Tactile Systems Technology's average media sentiment score of 0.42 beat Inogen's score of 0.20 indicating that Tactile Systems Technology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tactile Systems Technology	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Inogen	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tactile Systems Technology presently has a consensus price target of $38.60, indicating a potential upside of 35.77%. Given Tactile Systems Technology's stronger consensus rating and higher probable upside, equities analysts clearly believe Tactile Systems Technology is more favorable than Inogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tactile Systems Technology	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.86
Inogen	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Tactile Systems Technology has higher earnings, but lower revenue than Inogen. Inogen is trading at a lower price-to-earnings ratio than Tactile Systems Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tactile Systems Technology	$329.52M	1.95	$19.09M	$0.88	32.31
Inogen	$348.67M	0.50	-$22.75M	-$0.91	N/A

Tactile Systems Technology has a beta of 0.79, meaning that its stock price is 21% less volatile than the broader market. Comparatively, Inogen has a beta of 1.58, meaning that its stock price is 58% more volatile than the broader market.

Summary

Tactile Systems Technology beats Inogen on 12 of the 16 factors compared between the two stocks.

How does Inogen compare to Spyglass Pharma?

Spyglass Pharma (NASDAQ:SGP) and Inogen (NASDAQ:INGN) are both small-cap medical equipment companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, media sentiment, institutional ownership and earnings.

Spyglass Pharma has a net margin of 0.00% compared to Inogen's net margin of -7.08%. Spyglass Pharma's return on equity of 0.00% beat Inogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyglass Pharma	N/A	N/A	N/A
Inogen	-7.08%	-12.90%	-8.27%

In the previous week, Spyglass Pharma had 2 more articles in the media than Inogen. MarketBeat recorded 5 mentions for Spyglass Pharma and 3 mentions for Inogen. Inogen's average media sentiment score of 0.20 beat Spyglass Pharma's score of -0.12 indicating that Inogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyglass Pharma	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Inogen	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Spyglass Pharma presently has a consensus target price of $45.00, suggesting a potential upside of 122.00%. Given Spyglass Pharma's stronger consensus rating and higher probable upside, equities research analysts plainly believe Spyglass Pharma is more favorable than Inogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyglass Pharma	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
Inogen	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Spyglass Pharma has higher earnings, but lower revenue than Inogen. Inogen is trading at a lower price-to-earnings ratio than Spyglass Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyglass Pharma	N/A	N/A	N/A	-$6.41	N/A
Inogen	$348.67M	0.50	-$22.75M	-$0.91	N/A

89.9% of Inogen shares are owned by institutional investors. 2.5% of Inogen shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Spyglass Pharma beats Inogen on 8 of the 14 factors compared between the two stocks.

How does Inogen compare to MiMedx Group?

MiMedx Group (NASDAQ:MDXG) and Inogen (NASDAQ:INGN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk.

MiMedx Group has a beta of 1.45, indicating that its share price is 45% more volatile than the broader market. Comparatively, Inogen has a beta of 1.58, indicating that its share price is 58% more volatile than the broader market.

In the previous week, Inogen had 1 more articles in the media than MiMedx Group. MarketBeat recorded 3 mentions for Inogen and 2 mentions for MiMedx Group. MiMedx Group's average media sentiment score of 0.34 beat Inogen's score of 0.20 indicating that MiMedx Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiMedx Group	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Inogen	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MiMedx Group has a net margin of 7.88% compared to Inogen's net margin of -7.08%. MiMedx Group's return on equity of 21.03% beat Inogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiMedx Group	7.88%	21.03%	15.92%
Inogen	-7.08%	-12.90%	-8.27%

MiMedx Group has higher revenue and earnings than Inogen. Inogen is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiMedx Group	$418.63M	1.54	$48.58M	$0.20	21.60
Inogen	$348.67M	0.50	-$22.75M	-$0.91	N/A

MiMedx Group presently has a consensus price target of $8.50, suggesting a potential upside of 96.76%. Given MiMedx Group's stronger consensus rating and higher possible upside, research analysts plainly believe MiMedx Group is more favorable than Inogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Inogen	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

79.2% of MiMedx Group shares are owned by institutional investors. Comparatively, 89.9% of Inogen shares are owned by institutional investors. 2.5% of MiMedx Group shares are owned by company insiders. Comparatively, 2.5% of Inogen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

MiMedx Group beats Inogen on 12 of the 16 factors compared between the two stocks.

How does Inogen compare to Brainsway?

Inogen (NASDAQ:INGN) and Brainsway (NASDAQ:BWAY) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, analyst recommendations, earnings, profitability, dividends and valuation.

Brainsway has lower revenue, but higher earnings than Inogen. Inogen is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inogen	$348.67M	0.50	-$22.75M	-$0.91	N/A
Brainsway	$56.22M	11.53	$7.57M	$0.35	46.14

In the previous week, Brainsway had 7 more articles in the media than Inogen. MarketBeat recorded 10 mentions for Brainsway and 3 mentions for Inogen. Brainsway's average media sentiment score of 0.75 beat Inogen's score of 0.20 indicating that Brainsway is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inogen	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Brainsway	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Brainsway has a consensus target price of $15.67, suggesting a potential downside of 2.99%. Given Brainsway's stronger consensus rating and higher possible upside, analysts clearly believe Brainsway is more favorable than Inogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inogen	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Brainsway	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.20

89.9% of Inogen shares are owned by institutional investors. Comparatively, 30.1% of Brainsway shares are owned by institutional investors. 2.5% of Inogen shares are owned by company insiders. Comparatively, 19.0% of Brainsway shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Brainsway has a net margin of 15.68% compared to Inogen's net margin of -7.08%. Brainsway's return on equity of 12.28% beat Inogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inogen	-7.08%	-12.90%	-8.27%
Brainsway	15.68%	12.28%	7.75%

Inogen has a beta of 1.58, indicating that its share price is 58% more volatile than the broader market. Comparatively, Brainsway has a beta of 1.22, indicating that its share price is 22% more volatile than the broader market.

Summary

Brainsway beats Inogen on 13 of the 16 factors compared between the two stocks.

How does Inogen compare to NeuroPace?

Inogen (NASDAQ:INGN) and NeuroPace (NASDAQ:NPCE) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations, risk and media sentiment.

NeuroPace has lower revenue, but higher earnings than Inogen. NeuroPace is trading at a lower price-to-earnings ratio than Inogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inogen	$348.67M	0.50	-$22.75M	-$0.91	N/A
NeuroPace	$99.99M	5.27	-$21.47M	-$0.65	N/A

In the previous week, Inogen had 3 more articles in the media than NeuroPace. MarketBeat recorded 3 mentions for Inogen and 0 mentions for NeuroPace. NeuroPace's average media sentiment score of 0.87 beat Inogen's score of 0.20 indicating that NeuroPace is being referred to more favorably in the news media.

Company	Overall Sentiment
Inogen	Neutral
NeuroPace	Positive

Inogen has a beta of 1.58, indicating that its stock price is 58% more volatile than the broader market. Comparatively, NeuroPace has a beta of 1.88, indicating that its stock price is 88% more volatile than the broader market.

Inogen has a net margin of -7.08% compared to NeuroPace's net margin of -21.67%. Inogen's return on equity of -12.90% beat NeuroPace's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inogen	-7.08%	-12.90%	-8.27%
NeuroPace	-21.67%	-108.20%	-18.50%

89.9% of Inogen shares are owned by institutional investors. Comparatively, 78.8% of NeuroPace shares are owned by institutional investors. 2.5% of Inogen shares are owned by insiders. Comparatively, 19.2% of NeuroPace shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

NeuroPace has a consensus price target of $18.83, indicating a potential upside of 21.82%. Given NeuroPace's stronger consensus rating and higher probable upside, analysts plainly believe NeuroPace is more favorable than Inogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inogen	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
NeuroPace	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

Summary

NeuroPace beats Inogen on 10 of the 17 factors compared between the two stocks.

Get Inogen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INGN vs. The Competition

Export

Metric	Inogen	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$173.28M	$7.31B	$6.80B	$12.32B
Dividend Yield	N/A	1.32%	2.67%	9.67%
P/E Ratio	-7.07	49.84	26.92	24.18
Price / Sales	0.50	86.26	483.73	80.05
Price / Cash	N/A	26.15	49.71	59.37
Price / Book	0.91	6.94	10.67	6.25
Net Income	-$22.75M	$162.27M	$3.60B	$331.66M
7 Day Performance	0.31%	-2.61%	-1.00%	-1.32%
1 Month Performance	N/A	-1.16%	1.58%	-1.74%
1 Year Performance	1.42%	3.70%	24.12%	18.04%

Inogen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INGN Inogen	1.5118 of 5 stars	$6.43 +0.5%	N/A	+2.2%	$173.28M	$348.67M	N/A	1,030	News Coverage
TCMD Tactile Systems Technology	4.0349 of 5 stars	$29.04 -2.6%	$38.60 +32.9%	+194.3%	$672.85M	$329.52M	33.00	1,086	News Coverage
SGP Spyglass Pharma	1.706 of 5 stars	$19.90 -11.6%	$45.00 +126.1%	N/A	$665.32M	N/A	N/A	65
MDXG MiMedx Group	3.1808 of 5 stars	$4.08 -0.7%	$8.50 +108.3%	-35.0%	$612.17M	$418.63M	20.40	870	Positive News Upcoming Earnings
BWAY Brainsway	2.5678 of 5 stars	$14.10 -6.4%	$16.00 +13.5%	+167.2%	$604.35M	$52.22M	40.29	120	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INGN) was last updated on 7/22/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Inogen (INGN) Competitors

INGN vs. TCMD, SGP, MDXG, BWAY, and NPCE

How does Inogen compare to Tactile Systems Technology?

Summary

How does Inogen compare to Spyglass Pharma?

Summary

How does Inogen compare to MiMedx Group?

Summary

How does Inogen compare to Brainsway?

Summary

How does Inogen compare to NeuroPace?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INGN vs. The Competition

Inogen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Inogen (INGN) Competitors

INGN vs. TCMD, SGP, MDXG, BWAY, and NPCE

How does Inogen compare to Tactile Systems Technology?

Is TCMD or INGN more profitable?

Do institutionals & insiders have more ownership in TCMD or INGN?

Does the media refer more to TCMD or INGN?

Do analysts rate TCMD or INGN?

Which has better earnings & valuation, TCMD or INGN?

Which has more risk and volatility, TCMD or INGN?

Summary

How does Inogen compare to Spyglass Pharma?

Is SGP or INGN more profitable?

Does the media prefer SGP or INGN?

Do analysts prefer SGP or INGN?

Which has higher earnings and valuation, SGP or INGN?

Do institutionals and insiders hold more shares of SGP or INGN?

Summary

How does Inogen compare to MiMedx Group?

Which has more volatility & risk, MDXG or INGN?

Does the media refer more to MDXG or INGN?

Is MDXG or INGN more profitable?

Which has better earnings & valuation, MDXG or INGN?

Do analysts rate MDXG or INGN?

Do institutionals and insiders hold more shares of MDXG or INGN?

Summary

How does Inogen compare to Brainsway?

Which has preferable earnings and valuation, INGN or BWAY?

Does the media prefer INGN or BWAY?

Do analysts recommend INGN or BWAY?

Do institutionals & insiders have more ownership in INGN or BWAY?

Is INGN or BWAY more profitable?

Which has more volatility & risk, INGN or BWAY?

Summary

How does Inogen compare to NeuroPace?

Which has higher valuation and earnings, INGN or NPCE?

Does the media prefer INGN or NPCE?

Which has more volatility & risk, INGN or NPCE?

Is INGN or NPCE more profitable?

Do institutionals & insiders believe in INGN or NPCE?

Do analysts prefer INGN or NPCE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INGN vs. The Competition

Inogen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools